#SPARC is getting ready for a sparkling move #superchartzKey Levels:
Support: 360 to 350
Resistance: 389, 399, 421
Key Drivers:
Sun Pharma Advanced Research Company Ltd focuses on R&D of pharmaceutical products, earning revenue from license fees, royalties, and R&D services. In FY23, it obtained USFDA approval for Sezaby and filed for NDA of PDP-716 in collaboration with Visiox Pharma. The company primarily targets oncology & neurodegeneration, with 8 pipeline assets in various stages. It has shifted focus from New Drug Delivery Systems to New Chemical Entities, investing heavily in R&D. SPARC is part of the SunPharma Group, with significant corporate backing. It faced an IT security incident in March 2023, though business operations were not directly impacted. The company plans Phase 1 studies for SCD-153 and SBO-154 in FY24 and FY25, respectively, aiming for continued growth through collaborations and new preclinical programs.
